Table 5.
Prognostic Factors of 2-Year Overall Survival; Univariate Analysis and Multivariate Analysis.
| Prognostic Factor | All Patients (n = 150) | SBRT Alone (n = 28) | SBRT + TACE (n = 122) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | 2-Year OS (%) | UVA, P Value | MVA, P Value | Number | 2-year OS (%) | UVA, P Value | MVA, P Value | Number | 2-Year OS (%) | UVA, P Value | MVA, P Value | ||
| Age (years) | ≧75 | 73 | 82.6 | .4302 | − | 16 | 85.7 | .6658 | − | 57 | 81.6 | .4401 | − |
| <75 | 77 | 78.3 | 12 | 71.4 | 65 | 79.2 | |||||||
| Gender | Male | 99 | 78.6 | .9496 | − | 17 | 66.7 | .1239 | − | 82 | 80.2 | .5085 | − |
| Female | 51 | 83.5 | 11 | 100 | 40 | 80.9 | |||||||
| Performance status | 0 | 128 | 79.4 | .9229 | − | 21 | 75 | .8453 | − | 107 | 79.8 | .8667 | − |
| 1 or 2 | 22 | 87.8 | 7 | 100 | 15 | 84.6 | |||||||
| CTP class | A | 127 | 81.7 | .9236 | − | 23 | 75 | .4205 | − | 104 | 82.4 | .6846 | − |
| B | 23 | 72 | 5 | 100 | 18 | 68 | |||||||
| Viral infection | HCV | 109 | 81.3 | .3823 | − | 18 | 87.5 | .823 | − | 91 | 80.5 | .4614 | − |
| non-HCV | 41 | 77 | 10 | 66.7 | 31 | 79.1 | |||||||
| BCLC stage | 0 | 80 | 83.8 | .08 | − | 17 | 85.7 | .6979 | − | 63 | 83.3 | .043 | .6999 |
| A | 70 | 75.6 | 11 | 71.4 | 59 | 76 | |||||||
| T stage | T1 | 113 | 83.5 | .0492 | .1718 | 24 | 80 | .8522 | − | 89 | 83.7 | .0291 | .5556 |
| T2 | 37 | 70.4 | 4 | 75 | 33 | 69.8 | |||||||
| Greatest tumor dimensions | ≧20 mm | 63 | 83 | .0872 | − | 12 | 71.4 | .9944 | − | 47 | 84.4 | .0541 | − |
| <20 mm | 87 | 78.5 | 12 | 83.3 | 75 | 77.9 | |||||||
| Tumor location | Central | 13 | 77.9 | .8744 | − | 4 | 66.7 | .9239 | − | 9 | 85.7 | .7532 | − |
| Peripheral | 137 | 80.4 | 24 | 81.8 | 113 | 80.1 | |||||||
| Diagnosis history | Initial | 36 | 81.5 | .662 | − | 13 | 85.7 | .3214 | − | 23 | 79.6 | .8784 | − |
| Recurrence | 114 | 79.9 | 15 | 71.4 | 99 | 80.5 | |||||||
| Previous treatment (surgery) | Yes | 61 | 81 | .664 | − | 9 | 50 | .1394 | − | 52 | 83.5 | .8899 | − |
| No | 89 | 79.7 | 19 | 90 | 70 | 77.6 | |||||||
| Previous treatment (RFA/PEI) | Yes | 41 | 81.6 | .502 | − | 5 | 66.7 | .791 | − | 35 | 83.4 | .5137 | − |
| No | 109 | 79.8 | 23 | 81.8 | 87 | 79.3 | |||||||
| Adverse effects | <Grade 3 | 122 | 83.4 | .0222 | .0391 | 23 | 80 | .537 | − | 99 | 83.6 | .0085 | .0261 |
| ≧Grade 3 | 28 | 68.7 | 5 | 75 | 23 | 67.2 | |||||||
| Combination with TACE | Yes | 28 | 78.6 | .6583 | − | ||||||||
| No | 122 | 80.3 | |||||||||||
Abbreviations: BCLC; Barcelona Clinic Liver Cancer; CTP; Child-Turcotte-Pugh; HCV; hepatitis C virus; MVA, multivariate analyses; OS, overall survival; RFA/PEI; radiofrequency ablation/percutaneous ethanol injection; SBRT, stereotactic body radiotherapy; TACE, transcatheter arterial chemoembolization; UVA, univariate analyses